The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...

Take CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA), two biotechs specializing in gene editing. Finance, is $83.60; the latter earns a price target of $50.80 from ...

CRISPR technology has revolutionized genetic testing and disease detection, offering precise, rapid, and cost-effective diagnostic solutions. This gene-editing tool has been adapted for molecular ...

研究背景 基因编辑技术的精准化发展极大推动了生命科学研究，并为遗传病治疗提供了强有力的工具。先导编辑（Prime Editing, ...

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing ...

cellulolyticum wildtype and LM mutant to repress pta expression thereby reducing acetate production in these strains. Combined utilization of gene repression and Cas9 nickase genome editing realized a ...